The Effects of Sunitinib in Healthy and Cisplatin-Induced Rats

Basit Öğe Kaydı
dc.authoridKARATAS, Ozhan/0000-0002-2778-8059
dc.authoridARSLAN, YUSUF KEMAL/0000-0003-1308-8569
dc.authoridAKBAS, EMIN MURAT/0000-0002-3033-0073
dc.contributor.authorDemirtas, Levent
dc.contributor.authorGurbuzel, Mehmet
dc.contributor.authorAkbas, Emin Murat
dc.contributor.authorTahirler, Hilal
dc.contributor.authorKaratas, Ozhan
dc.contributor.authorArslan, Yusuf Kemal
dc.date.accessioned2025-05-04T16:47:37Z
dc.date.available2025-05-04T16:47:37Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractSunitinib is a multitargeted kinase inhibitor that inhibits many receptor tyrosine kinases and has been used in the treatment of gastrointestinal stromal tumors, metastatic renal cell carcinoma, and pancreatic neuroendocrine tumors. In this study, the effects of sunitinib given to rats, both alone and after stress with cisplatin, were investigated. The animals were divided into four groups - (1) control group (C) administered interperitoneally with a single dose 0.9 % saline, (2) Cis group administered a single dose (7 mg/kg) of cisplatin, (3) Sun group administered 10 mg/kg sunitinib for seven days, and (4) Cis+Sun group administered 10 mg/kg sunitinib for seven days after a single dose (7 mg/kg) of cisplatin. After these applications, the rats were sacrificed, and blood and tissue samples were taken for biochemical and histopathological evaluations. Sunitinib did not show any effect on urea, creatine, and kidney IL1 beta and TGF-beta 3 expression levels when administered alone; it increased ALT, AST, and IL-38 levels. When sunitinib was given to the cisplatin-induced rats, it was observed that the increase in ALT, AST, and IL-38 levels increased more than the rats that was given only sunitinib. According to the data obtained, sunitinib does not cause a significant change in kidney tissue under both normal and stress conditions, while it creates stress in liver tissue. In addition, its toxicity in the liver becomes more certain as a result of its combination with cisplatin.
dc.description.sponsorshipErzincan Binali Yildirim University [SAG-A-070114-0051]
dc.description.sponsorshipThis investigation was partially supported by a Research Fund of Erzincan Binali Yildirim University (SAG-A-070114-0051).
dc.identifier.doi10.1002/cbdv.202200704
dc.identifier.issn1612-1872
dc.identifier.issn1612-1880
dc.identifier.issue2
dc.identifier.pmid36703598
dc.identifier.scopus2-s2.0-85146780921
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1002/cbdv.202200704
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35673
dc.identifier.volume20
dc.identifier.wosWOS:000921419500001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofChemistry & Biodiversity
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250504
dc.subjectcisplatin
dc.subjectIL-38
dc.subjectnephrotoxicity
dc.subjectrat
dc.subjectsunitinib
dc.titleThe Effects of Sunitinib in Healthy and Cisplatin-Induced Rats
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu